113239-21-7 Usage
Uses
Used in Pharmaceutical Applications:
L-Serine, N-[[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetyl]is used as a pharmaceutical precursor for the synthesis of various biomolecules. Its unique structure allows it to be a key component in the development of new drugs and treatments.
Used in Research Applications:
In research, L-Serine, N-[[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetyl]is used as a substrate for enzymes, enabling scientists to study enzyme mechanisms and the synthesis of biomolecules. This helps in understanding the structure-activity relationships of similar compounds, which is vital for drug design and development.
Used in Drug Design and Development:
L-Serine, N-[[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetyl]is used as a structural template in drug design and development. Its chemical properties and structure provide insights into the creation of new compounds with potential therapeutic effects, contributing to the advancement of pharmaceutical research.
Check Digit Verification of cas no
The CAS Registry Mumber 113239-21-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,3,2,3 and 9 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 113239-21:
(8*1)+(7*1)+(6*3)+(5*2)+(4*3)+(3*9)+(2*2)+(1*1)=87
87 % 10 = 7
So 113239-21-7 is a valid CAS Registry Number.
113239-21-7Relevant academic research and scientific papers
Discovery of glutathione S-transferase inhibitors using dynamic combinatorial chemistry
Shi, Baolu,Stevenson, Ross,Campopiano, Dominic J.,Greaney, Michael F.
, p. 8459 - 8467 (2007/10/03)
Protein-directed dynamic combinatorial chemistry (DCC) relies on reversible chemical reactions that can function under the near-physiological conditions required by the biological target. Few classes of reaction have so far proven effective at generating
Compounds useful in treating sickle cell anemia
-
, (2008/06/13)
The present invention is directed to compounds of the general formula I and pharmaceutically acceptable salts thereof: STR1 wherein R=H or lower alkyl; R'=H, lower alkyl, benzyl, CH2 OH; A=(CH2)1 to 5, >C(CH3)s
